Development
Neosaxitoxin (NeoSTX) is a Site-1 sodium channel blocker that differs from existing local anesthetics
- Avoids local and systemic toxicities of existing agents
- profound synergy and prolonged duration when combined with existing local anesthetics and epinephrine
- No delivery system required
- Easily injectable, small gauge needles
Combination of NeoSTX, bupivacaine and epinephrine duplicates earlier work showing increased duration of analgesia vs Site-1 blocker alone
- NeoSTX-bupivacaine-epinephrine analgesic duration 6-fold longer than bupivacaine alone
- Rat sciatic nerve block
Neo3 has the potential to provide effective regional anesthesia and prolonged analgesia
Neo3 is a phase 2-ready injectable combining:
- NeoSTX– a novel site-1 sodium channel blocker with ultra-long duration of effect
- Bupivacaine & Epinephrine – which act synergistically with NeoSTX to enhance efficacy, prolong duration, and improve safety by limiting systemic exposure
Efficacy:
- Neo3 provides rapid, dense surgical anesthesia and prolonged post-surgical analgesia
Safety:
- No serious adverse events (SAEs), excellent safety profile to date
- NeoSTX has no direct cardiotoxicity.
- Systemic effects on respiratory and skeletal muscle strength are minimal at anticipated clinical doses
- Site-1 sodium channel blockers are largely devoid of toxicity to muscles and nerves and produce no local inflammation